The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Shionogi’s Net Profit Crosses 100 Billion Yen Mark in FY2017
Shionogi delivered records on all profit levels in the year ended March, with its net profit breaking the 100 billion yen mark for the first time, as its topline was lifted by rosy royalty income tied to its HIV franchise,…
To read the full story
Related Article
- Shionogi's FY2018 Sales Up 5.5% on HIV Royalties, Xofluza Notches 26.3 Billion Yen
May 10, 2019
- Shionogi’s Half-Year Profits Renew Records, but Crestor Generics Weigh on Topline
October 30, 2018
- Shionogi Earmarks 20 Billion Yen in Strategic R&D Investment
May 10, 2018
- Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
October 31, 2017
- Shionogi Ups Earnings Outlook on Milestone Scheme Change
October 24, 2017
- Shionogi Enjoys Rise in Japan Sales, Profits on HIV Royalty Revenue
May 11, 2017
BUSINESS
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- Towa Lifts Atomoxetine Shipment Curbs Across All Strengths
December 17, 2025
- Daiichi Sankyo Targets Cancer Cure with IO-ADC Combo Strategy
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…